This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Zhejiang Bossan Pharmaceutical Co. Ltd.. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Innovations of Shanghua Xia in EGFR Kinase Inhibition
Introduction
Shanghua Xia is a notable inventor based in Zhejiang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of EGFR kinase inhibitors. His work is characterized by a focus on innovative compounds that have the potential to impact cancer treatment.
Latest Patents
Shanghua Xia holds a patent for an EGFR kinase inhibitor and its preparation method and use. The invention provides a compound, as shown in formula (I), which is defined in detail within the patent description. This compound is recognized as an efficient EGFR inhibitor, showcasing its potential in therapeutic applications.
Career Highlights
Shanghua Xia is associated with Zhejiang Bossan Pharmaceutical Co. Ltd., where he continues to advance his research and development efforts. His work at the company emphasizes the importance of innovation in the pharmaceutical industry, particularly in the area of targeted cancer therapies.
Collaborations
Shanghua Xia collaborates with esteemed colleagues, including Dawei Ma and Qiang Yu. Their combined expertise contributes to the ongoing research and development of effective pharmaceutical solutions.
Conclusion
Shanghua Xia's contributions to the field of EGFR kinase inhibition highlight his role as an innovative inventor in the pharmaceutical industry. His work not only advances scientific knowledge but also holds promise for future therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile